Katayama, Sadao

Lecanemab in early Alzheimer's disease

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 5,678

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 2,932

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 304

Baseline characteristics of patients with early Alzheimer's disease enrolled in the pivotal trial of low-intensity pulsed ultrasound (LIPUS-AD)

Shimokawa, H., Akishita, M., Asada, T., Katayama, S., Hattori, Y., Yakushiji, Y., Taki, Y., Murai, H., Boku, Y., Tsujimoto, M., et al. (2025) · Journal of Alzheimer's Disease Reports

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 0